Clinical Trial

"Perfect Heartio" Drink and Cardiovascular Health

Recruiting
View on ClinicalTrials.gov →
Summary
Noncommunicable diseases (NCDs) such as type 2 diabetes (T2D) and cardiovascular disease (CVD) account for more deaths globally than any other condition. In 2018, the WHO reported that NCDs accounted for 71% of global deaths. They also showed that low- and middle-income countries are disproportionately affected by NCDs, accounting for 85% of NCD-related deaths among individuals aged 30-69 y. Among NCDs, CVD is the leading and fourth-leading causes of death, accounting for 19.5 million deaths worldwide in 2018. Furthermore, despite increasing global awareness, the prevalence of these conditions continues to increase at alarming rates. Deaths from CVD are expected to reach 23.6 million annually by 2030 from 17.6 million deaths in 2016. The underlying aetiology of these conditions is complex, as they can be influenced by several environmental, genetic, and behavioural factors. However, diet and nutrition play a particularly important role in these conditions, especially in the context of the double burden of malnutrition facing many low- and middle-income countries.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-24.
Trial Details
NCT Number NCT07048158
Lead Sponsor The Perfect Series Sdn Bhd
Collaborators: UCSI University
Conditions Cardiovascular Diseases, Lipid Metabolism Disorders
Enrollment 55 participants
Start Date 2025-04-01
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-08